Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA versus psilocybin assisted psychotherapy for treatment-resistant obsessive-compulsive disorder
ACTRN12622001525774Phase 2Recruiting
- Sponsor
- Australian National University
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing MDMA + psychotherapy with Psilocybin + psychotherapy (2 arms). Primary endpoint: Yale-Brown Obsessive-Compulsive Scale total score. Started Mar 2024; status: recruiting.
02
Drugs
midomafetaminepsilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on ACTRN12622001525774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001525774.